21498742

Source:http://linkedlifedata.com/resource/pubmed/id/21498742

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003234, umls-concept:C0038952, umls-concept:C0215136, umls-concept:C0278488, umls-concept:C0332157, umls-concept:C0671970, umls-concept:C0871261, umls-concept:C1514474, umls-concept:C1516213, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:issue	3
pubmed:dateCreated	2011-4-18
pubmed:abstractText	Capecitabine is a widely accepted option in pre-treated metastatic breast cancer (MBC) patients. However, little is known about specific activity in molecularly defined subgroups of patients. Here, response, survival and prognostic factors were examined in a prospectively characterized cohort of human epidermal growth factor receptor 2 (HER2) negative MBC patients receiving capecitabine following anthracycline and taxane failure.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8102988
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Bridged Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/taxane
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1791-7530
pubmed:author	pubmed-author:BertucciFrançoisF, pubmed-author:EsterniBenjaminB, pubmed-author:ExtraJean-MarcJM, pubmed-author:GilabertMarineM, pubmed-author:GonçalvesAnthonyA, pubmed-author:JacquemierJocelyneJ, pubmed-author:MadroszykAnneA, pubmed-author:TarpinCaroleC, pubmed-author:ViensPatriceP
pubmed:issnType	Electronic
pubmed:volume	31
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1079-86
pubmed:meshHeading	pubmed-meshheading:21498742-Adult, pubmed-meshheading:21498742-Aged, pubmed-meshheading:21498742-Anthracyclines, pubmed-meshheading:21498742-Antineoplastic Agents, pubmed-meshheading:21498742-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21498742-Breast Neoplasms, pubmed-meshheading:21498742-Bridged Compounds, pubmed-meshheading:21498742-Deoxycytidine, pubmed-meshheading:21498742-Disease-Free Survival, pubmed-meshheading:21498742-Female, pubmed-meshheading:21498742-Fluorouracil, pubmed-meshheading:21498742-Humans, pubmed-meshheading:21498742-Middle Aged, pubmed-meshheading:21498742-Multivariate Analysis, pubmed-meshheading:21498742-Neoplasm Metastasis, pubmed-meshheading:21498742-Prognosis, pubmed-meshheading:21498742-Receptor, erbB-2, pubmed-meshheading:21498742-Taxoids, pubmed-meshheading:21498742-Treatment Outcome
pubmed:year	2011
pubmed:articleTitle	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
pubmed:affiliation	Oncologie Médicale, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, INSERM U891, 232, boulevard Sainte Marguerite, 13009 Marseille, France.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't